Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Young and precancerous: 28-year-old helps fight aggressive oral cancer

Young and precancerous: 28-year-old helps fight aggressive oral cancer

Participate in Research Sep 11, 2017 4 minutes

"I say yes to participating in research because otherwise we wouldn’t have the medications we have today. It’s about giving back."

– Michael Haack, Vancouver

During a routine trip to the dentist, Michael Haack was told that he had a white patch on his tongue. Haack did not have a history of mouth injuries or gum disease, so the news came as a surprise.

“My dentist told me that it resembled a freckle in my mouth,” explains the 28-year-old executive director of a local political organization. “He told me that it was an oral lesion, and that we would need to monitor it going forward.”

At the time, Haack thought little of the spot. However, over the next three years and three annual checkups, it progressed in size. His dentist ordered a biopsy and the results confirmed mild oral dysplasia—abnormal lesions, often white or red, within oral tissues that have the potential to develop into cancer.

“I couldn’t believe it,” Haack says. “I’m a young, healthy person. I wasn’t expecting that kind of news at all.”

Aggressive cancer with no progression prevention

Over 300,000 oral cancer diagnoses are made worldwide each year, including more than 50,000 cases in North America and approximately 500 cases in British Columbia, where numbers are projected to increase in the future. Due to the aggressive nature of the disease, the best line of defense is to stop it as soon as possible.

There is currently no accepted treatment available for mild or moderate dysplasia; however, Haack was referred to a clinical trial—conducted through Vancouver Coastal Health Research Institute—that prescribes metformin to patients with pre-cancerous oral lesions.

“This is the first really promising idea for how to prevent the progression of oral cancers,” says Dr. Denise Laronde, a co-principal investigator of the phase 2a metformin for oral cancer prevention clinical trial.

“This trial could give us our first line of defense against oral cancers, as no agreed upon treatment for low-grade pre-oral cancers currently exists.”

Fighting oral cancer tooth and nail

Haack and other participants in the clinical trial received a biopsy to confirm the presence of an oral lesion. They also provided blood and saliva samples and underwent a physical exam. Each participant received a regular dose of metformin for 12 weeks under the direction of clinicians. When their trial period was complete, participants had another biopsy and follow-up appointment.

The results of the study will help clinicians better understand whether metformin can prevent the progression of oral cancers and save patients from more aggressive treatment, such as surgery and other cancer treatments.

Dr. Denise Laronde is a Vancouver Coastal Health research affiliate, an associate professor in the Faculty of Dentistry at the University of British Columbia and the acting director of the BC Oral Cancer Prevention Program.

“With severe dysplasia, people will often receive surgery to excise the lesion,” says Dr. Laronde. “It’s important to find treatments while someone is still pre-cancerous to prevent further harm.”

Metformin has been used to treat patients with diabetes for over 50 years, and recent research shows that it can also prevent certain types of cancer, such as prostate and colon cancers. Clinical trials like this one provide new insights into and potential applications for repurposing this safe and effective prescription drug.

“It was so easy to participate in the trial,” says Haack, “and knowing that I might be helping to advance treatments for other patients is incredibly rewarding.”

Haack will soon be studying towards a master of business degree and is an avid volunteer with the SPCA and Vancouver Pride Society. He says if the opportunity presents itself again, he would gladly participate in another clinical trial.

“I am really happy that I had the opportunity to play a small part in moving the process along,” says Haack. “I would definitely be interested in participating in the next phase of this trial or in a different one.”

Physicians and dentists may refer patients with mild or moderate dysplasia to the NextGen Clinic at: orca@bccrc.ca.

THIS IS ONE PATIENT’S STORY OF PARTICIPATING IN A CLINICAL TRIAL. YOUR EXPERIENCE MAY DIFFER. LEARN MORE ABOUT CLINICAL TRIALS BEFORE PARTICIPATING.

Related Articles

Ask an expert: Can brushing and flossing prevent oral cancer?

3D printing software could advance jaw reconstruction surgery

Too much and conflicting information might be the root of tooth decay in kids

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy